Tuesday - July 16, 2019
University of Texas-MD Anderson Cancer Center: Triplet-Targeted Therapy Improves Survival for Patients With Advanced Colorectal Cancer, BRAF Mutations
July 10, 2019
HOUSTON, Texas, July 10 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release:

* * *

- Phase III trial may change standard of care for up to 15 percent of colorectal cancer patients

* * *

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products